Vitru AAQS
Delisted
The The AAQS of Vitru (VTRU) as of Oct 23, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
4
YoY
0.00%
Last updated:
Vitru has a current AAQS of 4.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Vitru in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Vitru in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Vitru AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
4.00 BRL
Jan 1, 2019
4.00 BRL
Jan 1, 2020
4.00 BRL
Jan 1, 2021
4.00 BRL
Jan 1, 2022
4.00 BRL
Jan 1, 2023
4.00 BRL
| YEAR | AAQS | YoY |
|---|---|---|
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Vitru Stock analysis
What does Vitru do? Vitru Ltd is a British company specializing in the production and sale of high-quality and innovative implants and medical devices. The company was founded in 2011 and is based in London. Its initial focus was on developing products for human body reconstruction, including implants for knees, hips, and shoulders, as well as products for tendon and ligament repair. Vitru produces high-quality products that meet the highest standards by using state-of-the-art technologies and materials. The company has quickly become a leading provider in this market and continues to expand its offerings and expertise. This includes not only the manufacturing of implants but also the development and production of instruments and procedures that enable more precise and efficient surgeries for doctors and surgeons. Vitru also offers products and services in the areas of phenotyping and genotyping, collecting data on a person's genetic characteristics and using that information for personalized medicine and diagnostics. Another business field of Vitru is 3D printing. By utilizing 3D printing technology, the company can rapidly manufacture products and better meet customer needs. Vitru offers a wide range of implants that can be customized to individual customer requirements. In this context, Vitru has also engaged in the production of masks and other facial protection products to contribute to the fight against the COVID-19 pandemic. Vitru's products are known for their high quality, durability, and functionality. They are distributed both in the UK and worldwide and are used in orthopedics, neurosurgery, and other medical specialties. The company has a clear mission to be a global leader in the development and manufacturing of medical devices and implants tailored to the needs of patients and surgeons. To fulfill this mission, Vitru collaborates closely with professionals in the fields of medicine and technology. The company also works closely with hospitals and research institutions to stay up to date with the latest developments in medicine and technology and incorporate them into its products. An example of this is the development of knee implants specifically designed for women to better accommodate their needs. Overall, Vitru has established itself as an important player in the medical technology industry and is committed to improving healthcare for patients worldwide. Vitru is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Vitru stock
The AAQS of Vitru is 4 in 2023.
On Eulerpool you can find the complete historical development of The AAQS Vitru since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Vitru
All Key Metrics — Vitru
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth